RHK.DE
RHÖN-KLINIKUM Aktiengesellschaft [RHK.DE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RHK.DE Stock Summary
Top 10 Correlated Stocks
RHK.DE
In the News
RHK.DE Financial details
Company Rating
Neutral
Market Cap
763.1M
Income
38.71M
Revenue
1.46B
Book val./share
18.7
Cash/share
5.12
Dividend
0.15
Dividend %
1.5%
Employees
10.02K
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
20.36
Forward P/E
-
PEG
3.89
P/S
0.46
P/B
0.53
P/C
2.13
P/FCF
-
Quick Ratio
2.1
Current Ratio
2.28
Debt / Equity
0.12
LT Debt / Equity
0.11
-
-
EPS (TTM)
0.58
EPS next Y
-
EPS next Q
-
EPS this Y
52.63%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-2.25%
Revenue last 5Y
5.11%
Revenue Q/Q
3.94%
EPS Q/Q
35.29%
-
-
-
-
SMA20
-
SMA50
10%
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
2%
ROE
3%
ROC
0.03%
Gross Margin
67%
Oper. Margin
2%
Profit Margin
2%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.5-13.7
52W High
-16.15%
52W Low
+21.11%
RSI
44
Rel Volume
0.15
Avg Volume
3.06K
Volume
447
Perf Week
-2.68%
Perf Month
-9.17%
Perf Quarter
-2.68%
Perf Half Y
-6.03%
-
-
-
-
Beta
-0.029
-
-
Volatility
0.14%, 0.3%
Prev Close
0%
Price
10.9
Change
0.93%
RHK.DE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 19.48 | 20.32 | 20.94 | 21.6 | 24.99 | |
| Net income per share | 0.65 | 0.04 | 0.42 | 0.38 | 0.58 | |
| Operating cash flow per share | 0.71 | 1.69 | 1.46 | 0.62 | 1.79 | |
| Free cash flow per share | -1 | 0.24 | 0.29 | -0.25 | 0.85 | |
| Cash per share | 3.52 | 3.98 | 4.48 | 4.56 | 5.12 | |
| Book value per share | 17.35 | 17.41 | 17.9 | 18.28 | 18.7 | |
| Tangible book value per share | 15.05 | 15.07 | 15.58 | 16.02 | 16.5 | |
| Share holders equity per share | 17.35 | 17.41 | 17.9 | 18.28 | 18.7 | |
| Interest debt per share | 2.62 | 2.51 | 2.43 | 2.42 | 2.23 | |
| Market cap | 1.18B | 1.1B | 967.92M | 1.03B | 682.77M | |
| Enterprise value | 1.22B | 1.17B | 1B | 1.12B | 626.56M | |
| P/E ratio | 27.16 | 448.43 | 34.21 | 41.13 | 17.64 | |
| Price to sales ratio | 0.9 | 0.81 | 0.69 | 0.72 | 0.41 | |
| POCF ratio | 24.85 | 9.75 | 9.93 | 25.04 | 5.71 | |
| PFCF ratio | -17.49 | 67.76 | 49.13 | -61.19 | 12.04 | |
| P/B Ratio | 1.01 | 0.95 | 0.81 | 0.85 | 0.55 | |
| PTB ratio | 1.01 | 0.95 | 0.81 | 0.85 | 0.55 | |
| EV to sales | 0.94 | 0.86 | 0.71 | 0.77 | 0.37 | |
| Enterprise value over EBITDA | 9.69 | 14.29 | 9.98 | 10.39 | 13.71 | |
| EV to operating cash flow | 25.79 | 10.36 | 10.27 | 27 | 5.24 | |
| EV to free cash flow | -18.15 | 72.03 | 50.83 | -65.98 | 11.05 | |
| Earnings yield | 0.04 | 0 | 0.03 | 0.02 | 0.06 | |
| Free cash flow yield | -0.06 | 0.01 | 0.02 | -0.02 | 0.08 | |
| Debt to equity | 0.15 | 0.14 | 0.13 | 0.13 | 0.12 | |
| Debt to assets | 0.11 | 0.1 | 0.1 | 0.09 | 0.08 | |
| Net debt to EBITDA | 0.35 | 0.85 | 0.33 | 0.75 | -1.23 | |
| Current ratio | 2.15 | 2.07 | 2.24 | 2.37 | 2.35 | |
| Interest coverage | 18.93 | 1.43 | 9.54 | 8.81 | -5.27 | |
| Income quality | 0.87 | 29.05 | 3.56 | 1.23 | 3.09 | |
| Dividend Yield | 0.02 | 0 | 0 | 0 | 0.01 | |
| Payout ratio | 0.45 | 0 | 0 | 0 | 0.26 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0.04 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.11 | 0.11 | 0.11 | 0.11 | 0.1 | |
| Capex to operating cash flow | -2.42 | -0.86 | -0.8 | -1.41 | -0.53 | |
| Capex to revenue | -0.09 | -0.07 | -0.06 | -0.04 | -0.04 | |
| Capex to depreciation | -1.68 | -1.39 | -1.11 | -0.84 | -0.96 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 15.89 | 3.8 | 13.05 | 12.43 | 15.6 | |
| ROIC | 0.03 | 0 | 0.02 | 0.02 | -0.01 | |
| Return on tangible assets | 0.03 | 0 | 0.02 | 0.02 | 0.02 | |
| Graham Net | 0.39 | 0.62 | 1.21 | 1.88 | 2.34 | |
| Working capital | 300.64M | 293.06M | 337.76M | 397.53M | 453.74M | |
| Tangible asset value | 1.01B | 1.01B | 1.04B | 1.07B | 1.1B | |
| Net current asset value | 116.88M | 126.99M | 170.26M | 235.1M | 290.11M | |
| Invested capital | 0.15 | 0.14 | 0.13 | 0.13 | 0.12 | |
| Average receivables | 277.99M | 279.84M | 268.54M | 309.05M | 369.32M | |
| Average payables | 100.17M | 82.58M | 76.6M | 71.24M | 68.41M | |
| Average inventory | 27.19M | 31.84M | 34.18M | 33.22M | 33.77M | |
| Days sales outstanding | 83.07 | 70.56 | 71.37 | 86.82 | 86.13 | |
| Days payables outstanding | 75.56 | 69.73 | 61.48 | 57.2 | 15.88 | |
| Days of inventory on hand | 25.44 | 30.45 | 28.09 | 27.23 | 8.13 | |
| Receivables turnover | 4.39 | 5.17 | 5.11 | 4.2 | 4.24 | |
| Payables turnover | 4.83 | 5.23 | 5.94 | 6.38 | 22.99 | |
| Inventory turnover | 14.34 | 11.99 | 12.99 | 13.4 | 44.9 | |
| ROE | 0.04 | 0 | 0.02 | 0.02 | 0.03 | |
| Capex per share | -1.71 | -1.45 | -1.16 | -0.87 | -0.94 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.66 | 5.4 | 5.48 | 5.39 | 5.6 | |
| Net income per share | 0.13 | 0.09 | 0.09 | 0.17 | 0.23 | |
| Operating cash flow per share | 0.52 | 0.49 | 0.49 | 0.49 | 0 | |
| Free cash flow per share | 0.52 | 0.49 | 0.49 | 0.49 | 0 | |
| Cash per share | 4.56 | 6.46 | 4.19 | 7 | 5.12 | |
| Book value per share | 18.28 | 18.37 | 18.31 | 18.48 | 18.7 | |
| Tangible book value per share | 16.02 | 16.13 | 16.07 | 16.26 | 16.5 | |
| Share holders equity per share | 18.28 | 18.37 | 18.31 | 18.48 | 18.7 | |
| Interest debt per share | 2.38 | 2.26 | 0.14 | 2.26 | 2.19 | |
| Market cap | 1.03B | 873.55M | 789.87M | 796.57M | 682.77M | |
| Enterprise value | 1.12B | 935.7M | 721.8M | 793.27M | 626.57M | |
| P/E ratio | 29.51 | 34.89 | 34.46 | 17.83 | 10.98 | |
| Price to sales ratio | 2.73 | 2.42 | 2.15 | 2.21 | 1.82 | |
| POCF ratio | 29.54 | 26.78 | 23.95 | 24.43 | 0 | |
| PFCF ratio | 29.54 | 26.78 | 23.95 | 24.43 | 0 | |
| P/B Ratio | 0.85 | 0.71 | 0.64 | 0.64 | 0.55 | |
| PTB ratio | 0.85 | 0.71 | 0.64 | 0.64 | 0.55 | |
| EV to sales | 2.94 | 2.59 | 1.97 | 2.2 | 1.67 | |
| Enterprise value over EBITDA | 36.88 | 38.51 | 28.77 | 24.96 | 19.57 | |
| EV to operating cash flow | 31.85 | 28.69 | 21.88 | 24.33 | 0 | |
| EV to free cash flow | 31.85 | 28.69 | 21.88 | 24.33 | 0 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0.03 | 0.04 | 0.04 | 0.04 | 0 | |
| Debt to equity | 0.13 | 0.12 | 0.01 | 0.12 | 0.12 | |
| Debt to assets | 0.09 | 0.09 | 0 | 0.09 | 0.08 | |
| Net debt to EBITDA | 2.67 | 2.56 | -2.71 | -0.1 | -1.76 | |
| Current ratio | 2.37 | 2.29 | 2.27 | 2.28 | 2.35 | |
| Interest coverage | 11.06 | 7.47 | 5.22 | 14.16 | 18.39 | |
| Income quality | 4 | 5.21 | 5.76 | 2.92 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.11 | 0.1 | 0.1 | 0.1 | 0.1 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.34 | 6.22 | 5.94 | 8.33 | 9.89 | |
| ROIC | 0.01 | 0 | 0 | 0.01 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | 0 | 0.01 | 0.01 | |
| Graham Net | 1.88 | 2.26 | 1.71 | 2.55 | 2.34 | |
| Working capital | 397.53M | 407.57M | 411.21M | 431.04M | 453.74M | |
| Tangible asset value | 1.07B | 1.08B | 1.08B | 1.09B | 1.1B | |
| Net current asset value | 235.1M | 250.32M | 253.76M | 273.95M | 290.11M | |
| Invested capital | 0.13 | 0.12 | 0.01 | 0.12 | 0.12 | |
| Average receivables | 294.22M | 288.13M | 315.05M | 318.12M | 316.57M | |
| Average payables | 65.73M | 66.55M | 61.57M | 59.76M | 63.16M | |
| Average inventory | 32.83M | 33.59M | 34.37M | 34.06M | 33.73M | |
| Days sales outstanding | 81.71 | 57.84 | 97.64 | 59.48 | 94.72 | |
| Days payables outstanding | 52.9 | 47.36 | 46.13 | 44.23 | 15.18 | |
| Days of inventory on hand | 25.18 | 25.41 | 26.79 | 24.72 | 7.77 | |
| Receivables turnover | 1.1 | 1.56 | 0.92 | 1.51 | 0.95 | |
| Payables turnover | 1.7 | 1.9 | 1.95 | 2.03 | 5.93 | |
| Inventory turnover | 3.57 | 3.54 | 3.36 | 3.64 | 11.58 | |
| ROE | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
RHK.DE Frequently Asked Questions
What is RHÖN-KLINIKUM Aktiengesellschaft stock symbol ?
RHÖN-KLINIKUM Aktiengesellschaft is a DE stock and trading under the symbol RHK.DE
What is RHÖN-KLINIKUM Aktiengesellschaft stock quote today ?
RHÖN-KLINIKUM Aktiengesellschaft stock price is $10.9 today.
Is RHÖN-KLINIKUM Aktiengesellschaft stock public?
Yes, RHÖN-KLINIKUM Aktiengesellschaft is a publicly traded company.
Company Profile
- Volume Average 3.06K
- Market Capitalization 763.1M
- Employee 10.02K
- CEO Dr. Tobias Kaltenbach
- Headquarters Bad Neustadt an der Saale,DE
- IPO Date 1998-11-25
-
Website
https://www.rhoen-klinikum-ag.com 
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand surgery, neurological, psychosomatic, addiction therapy facilities, ophthalmology, trauma surgery, dentistry, thoracic, pulmonary, vascular, tumors, neurological conditions, and treatment of spinal column, joints, and heart diseases. It operates eight hospitals and 5,420 beds/places at five medical sites. The company is based in Bad Neustadt an der Saale, Germany.
